L 651582

Drug Profile

L 651582

Alternative Names: CAI; Carboxyamidotriazole; EP 00151529; NSC 609974

Latest Information Update: 22 Feb 2008

Price : $50

At a glance

  • Originator Merck & Co
  • Developer National Cancer Institute (USA)
  • Class Antineoplastics; Small molecules; Triazoles
  • Mechanism of Action Angiogenesis inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ovarian cancer; Peritoneal cancer; Prostate cancer

Most Recent Events

  • 23 Jul 2002 A study has been added to the adverse events and Cancer therapeutic trials section
  • 14 Aug 2001 A clinical study in patients with solid tumours has been added to the Cancer therapeutic trials and adverse events sections
  • 09 Nov 1999 A study has been added to the therapeutic trials, adverse events and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top